Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response.Gabriele Missale, Carlo Ferrari, Roberto Bertoni et al.|Journal of Clinical Investigation|1996Cited by 661
Effects of interferon treatment on the antiviral T-cell response in hepatitis C virus genotype 1b- and genotype 2c-infected patientsGabriele Missale, Carlo Ferrari, V. Lamonaca et al.|Hepatology|1997Cited by 65
Role of innate and adaptive immunity in the efficacy of anti-HER2 monoclonal antibodies for HER2-positive breast cancerAntonino Musolino, Maria Michiara, Daniela Boggiani et al.|Critical Reviews in Oncology/Hematology|2020Cited by 21
Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer—Immun-HER trial (GOIRC-01-2016)Benedetta Pellegrino, Antonino Musolino, Chiara Tommasi et al.|Journal for ImmunoTherapy of Cancer|2023Cited by 10
A randomized phase III trial comparing sorafenib plus best supportive care (BSC) versus BSC alone in Child-Pugh B patients (pts) with advanced hepatocellular carcinoma (HCC): The BOOST study.Bruno Daniele, Federica Perrone, Massimo Di Maïo et al.|Journal of Clinical Oncology|2012Cited by 4